Cabaletta Bio

📍 Philadelphia, United States🗓 Founded 2017👥 170 employees💰 Last funded Jul 2023
Biotechnology Research🌐 cabalettabio.com
Website LinkedIn
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus and myositis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.
2
Total investors
1
Early stage
0
Mid stage
1
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Cabaletta Bio?
Cabaletta Bio has 2 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did Cabaletta Bio last raise funding?
The most recent investment in Cabaletta Bio recorded on gritt.io was in July 2023.
When was Cabaletta Bio founded?
Cabaletta Bio was founded in 2017.
What industry is Cabaletta Bio in?
Cabaletta Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Cabaletta Bio based?
Cabaletta Bio is headquartered in Philadelphia, United States.